SCHEMBL3933094

SCHEMBL3933094

CCN(CC)Cc1ccc(N/C(=C2\C(=O)Nc3cc(C(=O)OC)ccc32)c2ccc3nccnc3c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
RAB9A P51151 3/20 0.40
GAA P10253 2/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
NPC1 O15118 2/20 0.39
TP53 P04637 2/20 0.39
KMT2A Q03164 6/20 0.36
MEN1 O00255 5/20 0.36
POLB P06746 4/20 0.36
HTT P42858 3/20 0.36
LMNA P02545 1/20 0.36
CTDSP1 Q9GZU7 1/20 0.35
CASP1 P29466 1/20 0.35
TSHR P16473 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC7 Q8WUI4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5857500 1.00 MAPT (0.40) MAPTSMN1; SMN2RAB9AGAAKDM4E
SCHEMBL5857141 0.92 MAPT (0.40) MAPTSMN1; SMN2RAB9AGAAKDM4E
SCHEMBL5857145 0.92 MAPT (0.40) MAPTSMN1; SMN2RAB9AGAAKDM4E
SCHEMBL5856864 0.89 MAPT (0.37) MAPTSMN1; SMN2RAB9AGAAALDH1A1
SCHEMBL5857319 0.89 F10 (0.42) MAPTSMN1; SMN2RAB9AGAANPC1
SCHEMBL3935002 0.89 MAPT (0.37) MAPTSMN1; SMN2RAB9AGAAALDH1A1
SCHEMBL3935821 0.89 F10 (0.42) MAPTSMN1; SMN2RAB9AGAANPC1
SCHEMBL3942421 0.89 KDM4E (0.41) MAPTRAB9AGAAKDM4EALDH1A1
SCHEMBL3942424 0.89 KDM4E (0.41) MAPTRAB9AGAAKDM4EALDH1A1
SCHEMBL3934767 0.88 NPC1 (0.49) MAPTSMN1; SMN2RAB9AGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1551830-B1 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS BOEHRINGER INGELHEIM PHARMA (DE) 2009-04-08 EP disclosed
US-7148249-B2 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-12-12 US disclosed
EP-1551830-A2 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-07-13 EP disclosed
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-03-10 US disclosed
WO-2004026829-A2 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments CDK1, CDK2, CDK3 MAPT 1798/4885SMN1; SMN2 4299/4885RAB9A 3709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.